Table 2.
Analysis of incidence of hospitalization for RSV.
| No. | Univariate | Multivariate | ||||
| Hospitalization (n = 23) | Non hospitalization (n = 475) | P value | Odds ratio | 95% CI | P value | |
| Demographic characteristics | ||||||
| Sex | .39 | |||||
| Female | 13 (5.6%) | 218 (94.4%) | ||||
| Mean age in months at entry (SD) | 9.8 (5.7) | 9.5 (6.5) | .81 | |||
| Mean gestational age in weeks (SD) | 36.5 (3.8) | 35.6 (4.1) | .27 | |||
| Main indications for palivizumab | .05 | |||||
| Congenital heart disease (CHD) | 18 (3.6%) | 259 (52.0%) | ||||
| Preterm | 3 (0.6%) | 166 (33.3%) | ||||
| 21 trisomy without CHD | 2 (0.4%) | 50 (10.0%) | ||||
| RSV risk factors | ||||||
| History of cardiac surgery | 8 (34.8%) | 171 (36.0%) | 1.00 | |||
| Scheduled cardiac surgery | 7 (30.4%) | 26 (5.5%) | <.01 | |||
| Siblings | 20 (87.0%) | 284 (59.8%) | <.01 | 5.10 | 1.48–17.6 | <.01 |
| Cyanosis originating from CHD | 10 (43.5%) | 108 (22.7%) | .04 | 3.25 | 1.33–7.94 | <.01 |
| Preschool | 4 (17.4%) | 74 (15.6%) | .77 | 1.38 | 0.44–4.39 | .58 |
RSV = respiratory syncytial virus.